Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells 4,875 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 4,875 shares of the firm’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $22.72, for a total transaction of $110,760.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Anish Patel also recently made the following trade(s):

• On Thursday, April 11th, Anish Patel sold 17,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.03, for a total value of $438,025.00.
• On Monday, April 8th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The shares were sold at an average price of $18.60, for a total value of $90,675.00.
• On Wednesday, March 6th, Anish Patel sold 4,875 shares of Enliven Therapeutics stock. The stock was sold at an average price of $15.64, for a total transaction of $76,245.00.

Enliven Therapeutics Price Performance

Shares of NASDAQ ELVN traded down $0.21 during mid-day trading on Wednesday, hitting $24.49. 432,449 shares of the company’s stock traded hands, compared to its average volume of 246,453. The company’s 50-day moving average is $17.82 and its two-hundred day moving average is $14.96. Enliven Therapeutics, Inc. has a 1 year low of $9.80 and a 1 year high of $26.00. The company has a market capitalization of $1.15 billion, a P/E ratio of -11.18 and a beta of 1.05.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.09. Equities analysts anticipate that Enliven Therapeutics, Inc. will post -2.16 EPS for the current fiscal year.

Institutional Trading of Enliven Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new stake in shares of Enliven Therapeutics in the 3rd quarter worth approximately $157,000. China Universal Asset Management Co. Ltd. purchased a new position in Enliven Therapeutics in the 4th quarter worth $66,000. Exchange Traded Concepts LLC increased its holdings in Enliven Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock worth $121,000 after buying an additional 2,208 shares during the period. AJOVista LLC purchased a new position in shares of Enliven Therapeutics during the fourth quarter worth $28,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Enliven Therapeutics by 9.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after purchasing an additional 1,029 shares during the period. Institutional investors own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Mizuho began coverage on shares of Enliven Therapeutics in a research report on Tuesday, April 9th. They set a “buy” rating and a $34.00 target price for the company.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.